Updated NCCN Guidelines Now Include Zanubrutinib for WM
The new second-generation BTK inhibitor zanubrutinib is a preferred regimen for the treatment of symptomatic Waldenstrom's macroglobulinemia.
Source: medscape.com
Stay updated with breaking news from Steven Treon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The new second-generation BTK inhibitor zanubrutinib is a preferred regimen for the treatment of symptomatic Waldenstrom's macroglobulinemia.
A National Cancer Institute researcher who has spent her entire career searching for a genetic link to Waldenstrom's macroglobulinemia has gleaned a few tantalizing clues.